First-line pharmacological interventions for T2D include insulin secretagogues (e.g., sulfonylureas), biguanides (e.g., metformin), α-glucosidase inhibitors (e.g., acarbose), and insulin sensitizers (e.g., thiazolidinediones) [5]. This evidence concerns the gene INS and type 2 diabetes mellitus.